As Health Problems Mount Patients Welcome New Treatments
June 14, 2022 at 11:00 AM EDT
Palm Beach, FL – June 14, 2022 – FinancialNewsMedia.com News Commentary – There are several serious health problems facing society today. Some, like heart disease, gastrointestinal diseases, cancer, and diabetes, pose a growing burden to health care systems and humanity alike. As health-aware patients seek a diagnosis from a younger age and populations live longer, cases are mounting. Here we discuss growing health problems with reference to Takeda Pharmaceutical (NYSE: TAK), Abbott Laboratories (NYSE: ABT), Bristol-Myers Squibb (NYSE: BMY), Novo Nordisk (NYSE: NVO), and Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL).
Takeda is making progress in treating cancer and gastrointestinal conditions, Bristol-Myers Squibb is making strides in oncology medications, Abbott labs is tackling diabetes, and Novo Nordisk is developing life-altering diabetes and weight loss drugs.
Meanwhile, heart failure comes in various forms, and some, such as acute myocarditis and diastolic heart failure, currently have no recognized standard of care.
Heart failure has remained the leading cause of death globally for the last 20 years, further exacerbated by mounting diabetes, obesity, and high blood pressure cases. This devastating condition comes in several forms, but ultimately leads to diminished quality of life and death.
Every year, over 550,000 new cases are diagnosed in the U.S. That’s why Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL) is working vigorously to develop treatments to help people live more comfortably with this destructive disease.
Cardiol Therapeutics is focused on researching and developing an anti-inflammatory and anti-fibrotic therapy to treat cardiovascular diseases (CVD). Its lead product candidate, CardiolRx, is a pharmaceutically produced oral formulation being clinically designed for use in cardiovascular medicine.
The company currently has one multi-national clinical trial ongoing, with another expected to commence shortly. Furthermore, it just announced its third FDA IND authorization for its flagship formulation CardiolRx in cardiovascular disease.
Altogether, the company is looking to treat acute myocarditis, recurrent pericarditis, and diastolic heart disease.
PHASE II RECURRENT PERICARDITIS TRIAL
Cardiol’s latest IND authorization is for a multicenter Phase II open-label pilot study of CardiolRx for recurrent pericarditis. This study will run parallel with the company’s multi-national Phase II acute myocarditis trial, which is expected to commence imminently.
The company will evaluate whether this intervention could be a therapeutic option for those who are intolerant to current medical treatment or who require long-term administration of corticosteroids to control their disease.
Dr. Allan L. Klein, Director Center of Pericardial Diseases and Professor of Medicine, Heart and Vascular Institute, Cleveland Clinic, will serve as study Chair and provide leadership throughout the trial.
Cardiol’s study is expected to enroll 25 patients at major clinical centers specializing in pericarditis in the United States. The study protocol has been designed in collaboration with well-established thought leaders in pericardial disease.
Pericarditis refers to inflammation of the pericardium – the membrane, or sac, surrounding the heart. Symptoms include debilitating chest pain, shortness of breath, and fatigue, which result in physical limitations, reduced quality of life, emergency department visits, and hospitalizations.
Causes of pericarditis can include infection (e.g., tuberculosis), systemic disorders such as autoimmune and inflammatory diseases, cancer, and post-cardiac injury syndromes.
Recurrent pericarditis is the reappearance of symptoms after a symptom-free period of at least 4–6 weeks following an episode of acute pericarditis. These recurrences appear in 15% to 30% of acute cases and usually within 18 months.
Up to 50% of patients with a recurrent episode of pericarditis experience more recurrences.
Cardiol believes there is a significant opportunity to develop a new oral, well-tolerated, and safe therapy for treating recurrent pericarditis to prevent multiple recurrences in the first place, particularly for colchicine-resistant, intolerant, refractory, and contraindicated patients, and steroid-dependent patients.
With the world facing intensifying healthcare challenges, doctors welcome breakthroughs in treating the most prevalent of diseases.
Takeda Pharmaceutical (NYSE: TAK) recently launched two new products, lung cancer med Exkivity and anti-cytomegalovirus drug Livtencity. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). The company also makes targeted R&D investments in Plasma-Derived Therapies and Vaccines.
Abbott Laboratories (NYSE: ABT) announced late-breaking clinical data that demonstrates its FreeStyle Libre® 3 system has an overall mean absolute relative difference (MARD) of 7.9%,1 making it the first and only 14-day continuous glucose monitoring (CGM) system to achieve a sub-8% overall MARD. The results were presented at the American Diabetes Association® (ADA) 82nd Scientific Sessions, June 3-7, 2022, in New Orleans.
Bristol-Myers Squibb Co (NYSE: BMY) is acquiring Turning Point Therapeutics, a leading precision oncology company. The acquisition brings Repotrectinib, a potential best-in-class, next-generation ros1/ntrk inhibitor with differentiated duration of response for patients with ros1-positive first-line non-small cell lung cancer. This drug is expected to launch in 2023. BMY’s all-cash tender offer will acquire all outstanding shares of turning point therapeutics for $76 per share.
Novo Nordisk A/S (NYSE: NVO) announced headline results from the main phases of its ONWARDS 1 (52 weeks) and ONWARDS 6 (26 weeks) phase 3a trials with once-weekly insulin icodec. In the trial, once-weekly insulin icodec appeared to have a safe and well-tolerated profile. This has the potential to become the ideal insulin for people with type 2 diabetes initiating insulin treatment.
DISCLAIMER: FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult =a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM has been compensated twenty six hundred dollars for news coverage of the current press releases issued by Cardiol Therapeutics by a non-affiliated third party. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Media Contact email: email@example.com – +1(561)325-8757
The post As Health Problems Mount Patients Welcome New Treatments appeared first on Financial News Media.